The company’s laboratory services and collaboration revenues rose in Q4, but these were offset by a decrease in product sales.
The company also reported that its preliminary full-year 2016 revenues rose 27 percent year over year, thanks to steady sales in its QuickFISH business.
The company recently presented preliminary results from two large-scale studies on tracking infections and drug resistance in large hospital systems.
Merck will provide OpGen with access to its library of bacterial pathogens in order to support OpGen's development of rapid DNA tests and a pathogens database.
The company attributed the fall in revenues to decreased sales of rapid pathogen identification and legacy genome mapping products.
The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.
The company said it will use the proceeds for research, development, product manufacturing, and other general corporate purposes.
As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.
The company attributed the increase in revenue to a $700,000 increase in product sales, particularly its rapid pathogen ID molecular diagnostic.
Despite the array of tests available, some lab directors are still seeking broader functionalities and capabilities from the systems they purchase.
Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.
An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.
The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.
In Nature this week: genotypes linked to hip osteoarthritis, and more.